Ecor1 Capital, Llc Purchases 22,689 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 22,689 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average price of $13.08 per share, with a total value of $296,772.12. Following the transaction, the director now directly owns 17,157,802 shares in the company, valued at $224,424,050.16. This trade represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, March 26th, Ecor1 Capital, Llc purchased 43,848 shares of Zymeworks stock. The shares were bought at an average price of $12.24 per share, for a total transaction of $536,699.52.
• On Friday, March 21st, Ecor1 Capital, Llc bought 31,033 shares of Zymeworks stock. The stock was bought at an average price of $12.78 per share, with a total value of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc acquired 58,306 shares of Zymeworks stock. The stock was bought at an average price of $12.64 per share, for a total transaction of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The shares were acquired at an average cost of $12.23 per share, with a total value of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc purchased 468,356 shares of Zymeworks stock. The stock was bought at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The stock was purchased at an average price of $11.49 per share, with a total value of $3,684,728.10.
• On Friday, January 17th, Ecor1 Capital, Llc bought 19,748 shares of Zymeworks stock. The shares were bought at an average price of $13.87 per share, for a total transaction of $273,904.76.
• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The shares were acquired at an average price of $14.01 per share, with a total value of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The stock was purchased at an average cost of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.

Zymeworks Price Performance

ZYME traded down $0.14 during midday trading on Friday, reaching $12.37. 320,353 shares of the company's stock traded hands, compared to its average volume of 598,132. The firm has a fifty day moving average of $13.60 and a two-hundred day moving average of $13.72. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70. The stock has a market capitalization of $860.67 million, a price-to-earnings ratio of -8.25 and a beta of 1.13.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright increased their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target for the company in a report on Monday, December 16th. Lifesci Capital began coverage on Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. Finally, Citigroup boosted their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $21.00.

Hedge Funds Weigh In On Zymeworks

Several institutional investors and hedge funds have recently modified their holdings of the stock. Blackstone Inc. lifted its stake in shares of Zymeworks by 2,171.4% in the 4th quarter. Blackstone Inc. now owns 569,715 shares of the company's stock worth $8,341,000 after purchasing an additional 544,633 shares during the period. Walleye Capital LLC purchased a new position in shares of Zymeworks during the fourth quarter valued at about $6,629,000. Schroder Investment Management Group bought a new position in shares of Zymeworks during the 4th quarter valued at approximately $4,892,000. Assenagon Asset Management S.A. lifted its position in Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock valued at $9,403,000 after purchasing an additional 311,107 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Zymeworks by 565.8% during the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock valued at $4,833,000 after purchasing an additional 280,544 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.